RNAC is a de-risked mRNA biotech company with a novel autologous CAR-T therapy (Descartes-08) for autoimmune diseases, backed by $150M in fresh non-dilutive financing extending runway to 2028, strong Phase 2b data, and a Phase 3 trial (AURORA) expected to readout Q1 2027. Key risks include clinical trial failure, competitive pressure from other CAR-T approaches, and execution risk in commercialization.